Abstract Search

ea0046oc3 | (1) | UKINETS2016

Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period

Horsch D , Kulke M , Caplin M , Anthony L , Bergsland E , Oberg K , Welin S , Warner R , Lombard-Bohas C , Kunz P , Valle J , Fleming D , Lapuerta P , Banks P , Pavel M

Introduction: TELESTAR was a pivotal, randomized phase 3 study evaluating telotristat etiprate (TE), a tryptophan hydroxylase inhibitor, among patients (pts) with carcinoid syndrome (CS). When added to somatostatin analogues (SSA), 250 mg tid and 500 mg tid TE each produced significantly greater bowel movement (BM) frequency reduction averaged over 12 weeks (wks) than placebo (PBO) plus SSA (P<0.001). Pts crossed over to open-label (OL) treatment with TE 500 mg ti...

0 shares

Endocrine Abstracts

Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period

BiosciAbstracts